Treatment overview > Emerging & Investigational >
 
Antiangiogenesis and Lymphoma

Last update: 04/19/2010

You can click AGENT SEARCH items to locate more information about it.  The ClinicalTrials.gov search will show trials for the agent that are recruiting for lymphoma.

	ABT-510  AGENT SEARCH: ASCO | ClinicalTrials.gov   "an investigational angiogenesis inhibitor, that belongs to a class of drugs that works by cutting off the blood supply that feeds tumors. Mimicking the behavior of a natural anti-angiogenic protein, thrombospondin-1 (TSP-1), ABT-510 is being evaluated to determine its potential to block multiple pro-angiogenic growth factors including VEGF, bFGF and IL-8. ABT-510 currently is being studied in Phase II clinical trials in various cancers including sarcoma, lymphoma, and kidney cancer." - yahoo.c Report on favorable safety profile and early signals of activity in a randomized phase IB trial - ASCO 2003
	Alpha interferon AGENT SEARCH: ASCO | ASH | ClinicalTrials.gov | PubMed   "IFN-alpha confers its antitumor activity, at least in part, by its antiangiogenic activity, which results from Sp1- and/or Sp3-mediated inhibition of VEGF gene transcription.." - NCI
	Bevacizumab AGENT SEARCH: ASCO | ASH | ClinicalTrials.gov | PubMed   "Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Non-Hodgkin’s lymphoma (NHL) patients with a high serum VEGF levels have an inferior overall survival compared to patients with low VEGF levels." - ASH

CC-5013 (Revlimid, lenalidomide) AGENT SEARCH: ASH | ASCO | Medscape | ClinicalTrials.gov | Web

Thalidomide appears to stop endothelial cells from forming new blood vessels and is a treatment for multiple myeloma and other types of cancer. However, it is harmful to fetuses, so women who are pregnant or plan to become pregnant should not take thalidomide. Lenalidomide (Revlimid), a drug that is similar to thalidomide, is potentially more active than thalidomide and is being tested in clinical trials - http://www.plwc.org 

• Cilengitide (EMD 121974) AGENT SEARCH: ASCO | ASH | ClinicalTrials.gov | PubMed
   
  Cilengitide (EMD 121974) inhibits two receptor proteins (proteins on cell surface), called integrins αvβ3 and αvβ5, which appear to be important in the process of angiogenesis. Cilengitide has been shown to inhibit angiogenesis and growth of several different experimental tumors in animals. - Clinicaltrials.gov

• Combretastatin AGENT SEARCH:  PubMed
   
  Combretastatin A-4 disodium phosphate (CA4DP), the lead compound in this series, has shown potent antivascular and antitumor effects in a wide variety of preclinical tumor models.^[77] Three phase I clinical trials of CA4DP involving a total of 96 patients with advanced cancers have been reported.^[78-80] Tumor pain was a unique side effect of combretastatin in these studies. In one study, 1 patient with anaplastic thyroid cancer had a complete response.^[78] Dose dependent reductions in tumor blood flow have been shown by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and PET at doses that were reasonably well tolerated by patients.^{[78,81-82] - http://www.medscape.com/viewprogram/3667_pnt} 
  
  Combretastatin A-4 prodrug and lymphoma: In vivo antitumor and antiangiogenic activity. Sanaa M. et.al.

• LY317615 TOPIC SEARCH: ASCO.org | ClinicalTrials.gov | Web 
  
  "LY317615 is a selective inhibitor of protein kinase Cβ with antiangiogenic activity as confirmed by its ability to inhibit VEGF-stimulated microvessel formation in rat corneal micropocket assays." - ASCO
  

• MS-275 and Isotretinoin AGENT SEARCH: ClinicalTrials.gov | Web
  
  MS-275 and isotretinoin may also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer.

Lend a hand to PAL: Donate Your Used Vehicle or 
Make an Email-Pledge or Donate by Mail  or ...

Related Abstracts

1: Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000 May 1;60(9):2527-34. PMID: 10811135; UI: 20269272

2 : Schaerer L, Schmid MH, Mueller B, Dummer RG, Burg G, Kempf W. Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density discriminates between cutaneous B-cell lymphomas and B-cell pseudolymphomas. Am J Dermatopathol. 2000 Apr;22(2):140-3. PMID: 10770434; UI: 20231203

3 : Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L, Dammacco F. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer. 2000 Jan 15;85(2):171-5. PMID: 10629073; UI: 20094792

4 : Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 1999 Nov 15;94(10):3334-9. PMID: 10552942; UI: 20021680

5 : Sharp JG, Chan WC. Detection and relevance of minimal disease in lymphomas. Cancer Metastasis Rev. 1999;18(1):127-42. Review. PMID: 10505551; UI: 99433370

6 : Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood. 1999 Oct 1;94(7):2461-8. PMID: 10498619; UI: 99428332

7: Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999 Aug;106(2):504-9. PMID: 10460612; UI: 99390203

8 : Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999 Mar;5(3):181-91. PMID: 10404515; UI: 99332594

9 : Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer. 1999 Feb;79(5-6):965-70. PMID: 10070898; UI: 99168446

10 : Michigami T, Nomizu M, Yamada Y, Dunstan C, Williams PJ, Munday GR, Yoneda T. Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide. Clin Exp Metastasis. 1998 Oct;16(7):645-54. PMID: 9932611; UI: 99129391

11 : Sola F, Capolongo L, Moneta D, Ubezio P, Grandi M. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule. Cancer Chemother Pharmacol. 1999;43(3):241-6. PMID: 9923555; UI: 99120430

12 : Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998 Dec 21;188(12):2349-56. PMID: 9858521; UI: 99077919

13 : Satake S, Kuzuya M, Miura H, Asai T, Ramos MA, Muraguchi M, Ohmoto Y, Iguchi A. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Cell. 1998 Mar;90(2):161-8. PMID: 9691433; UI: 98356462

14 : Ribatti D, Nico B, Vacca A, Marzullo A, Calvi N, Roncali L, Dammacco F. Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas? Br J Cancer. 1998 Jun;77(11):1900-6. No abstract available. PMID: 9667666; UI: 98330240

15 : Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998 Jul;153(1):103-8. PMID: 9665470; UI: 98328407

16 : Picchio GR, Sabbe RE, Gulizia RJ, McGrath M, Herndier BG, Mosier DE. The KSHV/HHV8-infected BCBL-1 lymphoma line causes tumors in SCID mice but fails to transmit virus to a human peripheral blood mononuclear cell graft. Virology. 1997 Nov 10;238(1):22-9. PMID: 9375005; UI: 98042438

17 : Vacca A, Moretti S, Ribatti D, Pellegrino A, Pimpinelli N, Bianchi B, Bonifazi E, Ria R, Serio G, Dammacco F. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer. 1997 Sep;33(10):1685-92. PMID: 9389934; UI: 98051373

18 : Matar P, Celoria GC, Font MT, Scharovsky OG. Angiogenesis induced by tumor-host interaction in the rat. J Exp Clin Cancer Res. 1997 Sep;16(3):249-53. PMID: 9387897; UI: 98047090

19 : Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997 Sep;183(1):44-50. PMID: 9370946; UI: 98038280

20 : Miles KA, Kelley BB. CT measurements of capillary permeability within nodal masses: a potential technique for assessing the activity of lymphoma. Br J Radiol. 1997 Jan;70:74-9. PMID: 9059299; UI: 97212443

21 : Angiolillo AL, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:158-67. PMID: 8958926; UI: 97118043

22 : Vacca A, Ribatti D, Fanelli M, Costantino F, Nico B, Di Stefano R, Serio G, Dammacco F. Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-Hodgkin's lymphomas. Leuk Lymphoma. 1996 Aug;22(5-6):473-81. PMID: 8882961; UI: 97037314

23 : Patey N, Vazeux R, Canioni D, Potter T, Gallatin WM, Brousse N. Intercellular adhesion molecule-3 on endothelial cells. Expression in tumors but not in inflammatory responses. Am J Pathol. 1996 Feb;148(2):465-72. PMID: 8579109; UI: 96163281

24 : Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol. 1996 Jan-Feb;56(1-2):45-53. PMID: 8599993; UI: 96178168

25 : Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma. 1995 Dec;20(1-2):27-38. Review. PMID: 8750620; UI: 96351965

26 : Bussolino F, Arese M, Montrucchio G, Barra L, Primo L, Benelli R, Sanavio F, Aglietta M, Ghigo D, Rola-Pleszczynski MR Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest. 1995 Aug;96(2):940-52. PMID: 7543496; UI: 95362858

27 : Sola F, Farao M, Ciomei M, Pastori A, Mongelli N, Grandi M. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis. 1995;15(5-6):222-31. PMID: 8765197; UI: 96348019

28 : Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994 Mar 1;56(5):681-8. PMID: 8314345; UI: 94148571

29 : Yamamoto T, Sudo K, Fujita T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res. 1994 Jan-Feb;14(1A):1-3. PMID: 7513139; UI: 94219794

30 : Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer. 1992 Aug;66(2):367-72. PMID: 1380282; UI: 92368865

31 : Sola F, Biasoli G, Pesenti E, Farao M, Della Torre P, Mongelli N, Grandi M. In vivo activity of novel sulphonic derivatives of distamycin A. EXS. 1992;61:459-62. PMID: 1377572; UI: 92314621

32 : Mariani M, Paio A, Ciomei M, Pastori W, Franzetti C, Melegaro G, Grandi M, Mongelli N. In vitro activity of novel sulphonic derivatives of distamycin A. EXS. 1992;61:455-8. PMID: 1377571; UI: 92314620

33 : Lugassy C, Hardy M, Peyrol S, Pages MP, Escande JP. Three-dimensional model of cancer and in vitro metastasis: application to non-Hodgkin malignant lymphoma. C R Acad Sci III. 1991;313(1):37-43. French. PMID: 1913248; UI: 92004868

34 : Ribatti D, Vacca A, Bertossi M, De Benedictis G, Roncali L, Dammacco F. Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Res. 1990 Mar-Apr;10(2A):401-6. PMID: 1693265; UI: 90267083

35 : Hoffer FA, Taylor GA, Spevak M, Ingber D, Fenton T. Metabolism of tumor regression from angiogenesis inhibition: 31P magnetic resonance spectroscopy. Magn Reson Med. 1989 Aug;11(2):202-8. PMID: 2476646; UI: 89384100

36 : Folkman J. Toward a new understanding of vascular proliferative disease in children. Pediatrics. 1984 Nov;74(5):850-6. PMID: 6208529; UI: 85037778

37 : Gleichmann E, van Elven F, Gleichmann H. Immunoblastic lymphadenopathy, systemic lupus erythematosus, and related disorders. Possible pathogenetic pathways. Am J Clin Pathol. 1979 Oct;72(4 Suppl):708-23. PMID: 40433; UI: 80039693

38. Olofsson B, Jeltsch M, Eriksson U, Alitalo K., Current biology of VEGF-B and VEGF-C, Curr Opin Biotechnol. 1999 Dec;10(6):528-35. Review, PMID: 10600689; UI: 20070825. (Ludwig Institute for Cancer Research, Box 240, Stockholm, SE-171 77, Sweden)

39. Miles KA, Kelley BB, CT measurements of capillary permeability within nodal masses: a potential technique for assessing the activity of lymphoma, Br J Radiol. 1997 Jan;70:74-9, PMID: 9059299; UI: 97212443

40. Pellet C, Lebbe C. [Kaposi's disease and HHV8: a new model of virus-induced tumorigenesis]. Pathol Biol (Paris). 2000 Jul;48(6):529-32. French. PMID: 10965529; UI: 20421034

41. Yao L, Pike SE, Setuda J, Pareka J, Gupta G, Raffeld M., Jaffe ES, Tosato G. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood. 2000 Sep 1;96(5):1900-5. PMID: 10961892; UI: 20417769

42. Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia. 2000 Aug;14(8):1477-82. PMID: 10942245; UI: 20395693

43. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Prueri G. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood. 2000 Jul 1;96(1):282-7. PMID: 10891463; UI: 20352013

44. Bredoux C, Uphoff CC, Drexler HG, Expression of tie receptor tyrosine kinase in human leukemia cell lines. Leuk Res. 1997 Jul;21(7):595-601. PMID: 9301679; UI: 97447228

45. Harris NL, Dvorak AM, Smith J, Dvorak HF, Fibrin deposits in Hodgkin's disease. Am J Pathol. 1982 Jul;108(1):119-29. PMID: 7046453; UI: 82227944

46. Angiolillo AL, Sgadari C, Tosato G., A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:158-67. PMID: 8958926; UI: 97118043

47. Harris NL, Dvorak AM, Smith J, Dvorak HF, Fibrin deposits in Hodgkin's disease. Am J Pathol. 1982 Jul;108(1):119-29. PMID: 7046453; UI: 82227944

48: Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F. |Related Articles

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas.
Br J Cancer. 1999 Feb;79(5-6):965-70.
PMID: 10070898

49:  Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E.

Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol. 2000 Nov;17(4):314-8. PMID: 11114711

50: Rosas R, Poo JL, Montemayor A, Isoard F, Majluf A, Labardini J. |Related Articles

[Utility of the copper/zinc ratio in patients with lymphoma or acute or chronic leukemias]. Rev Invest Clin. 1995 Nov-Dec;47(6):447-52. Spanish. PMID: 8850142